Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.

doi:10.1182/bloodadvances.2025016306

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.

Blood advances - 28 Oct 2025

Levis Mark J, Hamadani Mehdi, Logan Brent R, Jones Richard J, Singh Anurag K, Litzow Mark R, Wingard John R, Papadopoulos Esperanza B, Perl Alexander E, Soiffer Robert J, Ustun Celalettin, Oshima Masumi Ueda, Uy Geoffrey L, Waller Edmund K, Vasu Sumithira, Solh Melhem, Mishra Asmita, Muffly Lori S, Kim Hee-Je, Stelljes Matthias, Najima Yuho, Onozawa Masahiro, Thomson Kirsty, Chen Caroline, Hasabou Nahla, Rosales Matt, Hill Jason E, Gill Stanley C, Nuthethi Rishita, King Denise, Mendizabal Adam, Devine Steven M, Horowitz Mary M, Chen Yi-Bin

Abstract excerpt

ABSTRACT: We conducted a post hoc analysis of data from Blood and Marrow Transplant Clinical Trials Network 1506 (MORPHO), a randomized trial of gilteritinib vs placebo as posttransplantation maintenance for patients with FLT3-ITD-mutated acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (HCT), focusing the interactions between conditioning regimen intensity, measurable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to fms-Like Tyrosine Kinase 3

Share to Hematopoietic Stem Cell Transplantation

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to Pyrazines

Share to Transplantation Conditioning

Share to Transplantation, Homologous

Source

Open in PubMed Open full text

Identifiers

PMID: 40590852
DOI: 10.1182/bloodadvances.2025016306
PMCID: PMC12550156

Genes

FLT3
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.PMID 40590852Read ↗

Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party.Semantic proximity Read ↗

Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.Semantic proximity Read ↗

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.Semantic proximity Read ↗

Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.Semantic proximity Read ↗

Pre-MEASURE:<i>FLT3</i>-ITD and mutated<i>NPM1</i>measurable residual disease before allogeneic transplant in adults with AML in first remissionSemantic proximity Read ↗

Changes in Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for FLT3-ITD-mutated Acute Myeloid Leukemia in the FLT3 Inhibitor Era.Semantic proximity Read ↗

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.Semantic proximity Read ↗

Outcomes of patients with R/R FLT3mut+ AML treated with maintenance gilteritinib therapy after hematopoietic stem cell transplantation.Semantic proximity Read ↗

Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.Semantic proximity Read ↗

Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaSemantic proximity Read ↗

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.Semantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.